The expert consensus pathway provides recommendations for the evaluation and management of adults with myocarditis and long COVID following COVID-19 infection.

A study shows that individuals in the post-acute phase of COVID-19 exhibited increased risks and 12-month burdens of incident CV diseases, compared to individuals with no evidence of SARA-CoV-2 infection.

A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

The MICHELLE trial shows that extended post-discharge thromboprophylaxis with the DOAC rivaroxaban for 35 days improved clinical outcomes compared to no anticoagulation in patients with high risk of thromboembolism who were hospitalized due to COVID-19.

The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.

Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.

Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.

Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.